Clinical Trial Update: A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India. [Phase 3]

View source ↗

Summary

Pfizer completed a Phase 3 trial in adults in India to evaluate the safety and immune response of the 20-valent pneumococcal conjugate vaccine (Prevnar 20); res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 20 (20-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-10-24